No evidence that widely prescribed statins protect against prostate cancer

Researchers from the New England Research Institutes found that while men using statins did indeed have lower blood levels of androgens such as testosterone, it was more likely attributable to poor health rather than the use of statins. Their findings are published in the August issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

“The public health significance is that our study provides evidence that statins may not have a clinically meaningful impact on testosterone in the blood, although further studies should be done,” said study author, Susan A. Hall, Ph.D., a research scientist at the New England Research Institutes. “That doesn’t mean that statins may be lowering prostate cancer risk through one or more alternative pathways, but it doesn’t appear to be working through reduction of male hormones,

Statins lower cholesterol and are commonly prescribed to treat and prevent heart disease. Since cholesterol is required for the production of male hormones researchers have theorized that statins may reduce production of these hormones. A large, recent study found that men using statin drugs were at lowered risk of developing metastatic or fatal prostate cancer, especially if the drugs were used over a long period of time. But other studies on statin use and prostate cancer risk have had mixed results, according to Hall.

To study a narrow question − whether statin use reduces androgen concentrations in the blood − the researchers examined data from the Boston Area Community Health (BACH) survey, a population-based, NIH-sponsored, epidemiologic study. Data were collected between 2002 and 2005 on thousands of men and women with equal representation of African American, Caucasian and Hispanic populations.

The value of the BACH study, according to Hall, is that “we capture real world use of medications in the community, which might be a more realistic representation of their impact on the body, compared to outcomes seen in a clinical trial.”

Hall’s team studied the medical histories of 1,812 men, including 237 statin users, and analyzed their blood for “free” or unbound testosterone, for total testosterone, and for other associated compounds.

The researchers found no relationship between statin use and free testosterone and most of the other associated compounds. There was a significant association between statin use and level of total testosterone in the blood, but that association vanished when researchers considered the patients’ age, body weight, and history of cardiovascular disease and diabetes. “We know that men with higher body mass index, diabetes and cardiovascular disease tend to have lower testosterone levels, and this largely accounted for the drop in testosterone in statin users,” Hall said.

“In this study, statin use was just a marker for presence of other illnesses,” she said. “This study may inform that debate, however, by suggesting that any protective pathway offered by statins, if it exists, is not through androgen suppression.”

Source: American Association for Cancer Research

Low cholesterol associated with cancer in diabetics
Low levels of LDL cholesterol as well as high levels are associated with cancer in patients with type 2 diabetes, found a prospective cohort study published in CMAJ.
FDA investigates possible Vytorin link to cancer
(AP) -- Federal drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer.
Hair on a man's head offers clues about prostate cancer
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.
Researchers find cancer-inhibiting compound under the sea
University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.
Lowering cholesterol early in life could save lives
(PhysOrg.com) -- With heart disease maintaining top billing as the leading cause of death in the United States, a team of University of California, San Diego School of Medicine physician-researchers is proposing that aggressive intervention to lower cholesterol levels as early as childhood is the best approach available today to reducing the incidence of coronary heart disease.
Prostate cancer patients undergoing hormone therapy may experience cognitive effects
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate. Published in the September 1, 2008 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that clinicians and patients should be aware of these potential effects and watch closely for their appearance.
Pregnancy may help protect against bladder cancer
Pregnancy seems to confer some protection against bladder cancer in mice, scientists have found. Female mice that had never become pregnant had approximately 15 times as much cancer in their bladders as their counterparts that had become pregnant, according to new findings by investigators at the University of Rochester Medical Center.
Low testosterone appears to increase long-term risk of death
Men may not live as long if they have low testosterone, regardless of their age, according to a new study. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.

No evidence that widely prescribed statins protect against prostate cancer

Related stories:

News discussion: